Algorithmic Accountability and Anti-Corruption Governance: A Framework for Detecting Substandard and Falsified Medical Products

The proliferation of substandard and falsified (SF) medical products represents a critical failure of pharmaceutical governance that disproportionately harms populations in low- and middle-income countries. Criminological research has long documented the structural conditions that enable pharmaceutical corruption, from corporate crime in drug testing and manufacturing to the transnational networks that traffic falsified medicines across regulatory boundaries. While international anti-corruption instruments, notably the United Nations Convention Against Corruption (UNCAC) and the Council of Europe MEDICRIME Convention, provide legal frameworks to combat pharmaceutical corruption, significant enforcement gaps persist. Algorithmic decision-making systems are increasingly deployed to detect SF products within pharmaceutical supply chains, yet these systems operate largely outside established accountability frameworks and may themselves reproduce the structural biases that characterise global pharmaceutical markets. This article proposes an Algorithm Accountability Benchmark (AAB) designed to evaluate the transparency, fairness, and accountability of algorithms used in pharmaceutical product detection and regulatory enforcement. Drawing on the theoretical frameworks of criminogenic asymmetries, global anomie and dysnomie, and the concept of practices that are “lawful but awful,” the paper argues that algorithmic governance tools must be assessed not only for technical performance but also for their capacity to either reinforce or disrupt the structural conditions that enable pharmaceutical corruption. The AAB integrates anti-corruption governance principles derived from UNCAC with algorithmic accountability standards from the European Union Artificial Intelligence Act, offering a comprehensive evaluation methodology across prevention, detection, reporting, and enforcement dimensions. The article contributes to the growing interdisciplinary literature linking anti-corruption law, algorithmic governance, and global health security.

Authors

Institutions

Publication Details

Journal
Laws
Published
2026-10-13
DOI
https://doi.org/10.3390/laws15050137
Primary Topic
Pharmaceutical Quality and Counterfeiting
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Algorithmic Accountability and Anti-Corruption Governance: A Framework for Detecting Substandard and Falsified Medical Products

Νίκος Πασσάς, Ioannis Kakadiaris, Aisha Bukhari
Laws
Pharmaceutical Quality and Counterfeiting
article

Algorithmic Accountability and Anti-Corruption Governance: A Framework for Detecting Substandard and Falsified Medical Products

Νίκος Πασσάς, Ioannis Kakadiaris, Aisha Bukhari
article en

Abstract

The proliferation of substandard and falsified (SF) medical products represents a critical failure of pharmaceutical governance that disproportionately harms populations in low- and middle-income countries. Criminological research has long documented the structural conditions that enable pharmaceutical corruption, from corporate crime in drug testing and manufacturing to the transnational networks that traffic falsified medicines across regulatory boundaries. While international anti-corruption instruments, notably the United Nations Convention Against Corruption (UNCAC) and the Council of Europe MEDICRIME Convention, provide legal frameworks to combat pharmaceutical corruption, significant enforcement gaps persist. Algorithmic decision-making systems are increasingly deployed to detect SF products within pharmaceutical supply chains, yet these systems operate largely outside established accountability frameworks and may themselves reproduce the structural biases that characterise global pharmaceutical markets. This article proposes an Algorithm Accountability Benchmark (AAB) designed to evaluate the transparency, fairness, and accountability of algorithms used in pharmaceutical product detection and regulatory enforcement. Drawing on the theoretical frameworks of criminogenic asymmetries, global anomie and dysnomie, and the concept of practices that are “lawful but awful,” the paper argues that algorithmic governance tools must be assessed not only for technical performance but also for their capacity to either reinforce or disrupt the structural conditions that enable pharmaceutical corruption. The AAB integrates anti-corruption governance principles derived from UNCAC with algorithmic accountability standards from the European Union Artificial Intelligence Act, offering a comprehensive evaluation methodology across prevention, detection, reporting, and enforcement dimensions. The article contributes to the growing interdisciplinary literature linking anti-corruption law, algorithmic governance, and global health security.

LawsVol. 15(5)
Northeastern University (US), University of Houston (US)
Openalex Percentile: Top 11%
Pharmaceutical Quality and Counterfeiting
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.